Literature DB >> 14607088

Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases?

Joel N Buxbaum1.   

Abstract

Certain human diseases are associated with proteins that misfold and exhibit decreased solubility under physiological conditions. They result either from mutations that change the amino acid sequence of a protein, or from misfolded wild-type proteins, such as in Parkinson's disease and Alzheimer's disease. One subset--the amyloidoses--cause extracellular deposits that stain with the dye Congo red. Another subset is associated with intracellular deposits with non-Congophilic nuclear or cytoplasmic inclusions. Purified, recombinantly produced versions of some of the proteins that form intracellular aggregates can also display Congophilia, as well as other properties associated with the in vivo amyloidoses when examined under non-physiological conditions in vitro. Some of these purified proteins or protein fragments have never been identified as pathogenic in humans or animals. Despite potentially shared thermodynamic and kinetic processes involving the target molecules, the biology of these two subsets differs significantly.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607088     DOI: 10.1016/j.tibs.2003.09.009

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  17 in total

1.  Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.

Authors:  Douglas J Martin; Marina Ramirez-Alvarado
Journal:  Amyloid       Date:  2010-09       Impact factor: 7.141

2.  The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein.

Authors:  Richard W McLaughlin; Janelle K De Stigter; Laura A Sikkink; Elizabeth M Baden; Marina Ramirez-Alvarado
Journal:  Protein Sci       Date:  2006-06-02       Impact factor: 6.725

3.  The kinetics of nucleated polymerizations at high concentrations: amyloid fibril formation near and above the "supercritical concentration".

Authors:  Evan T Powers; David L Powers
Journal:  Biophys J       Date:  2006-04-07       Impact factor: 4.033

4.  Mechanisms of protein fibril formation: nucleated polymerization with competing off-pathway aggregation.

Authors:  Evan T Powers; David L Powers
Journal:  Biophys J       Date:  2007-09-21       Impact factor: 4.033

5.  Characterization of proteins associated with polyglutamine aggregates: a novel approach towards isolation of aggregates from protein conformation disorders.

Authors:  Yan Wang; Anatoli B Meriin; Catherine E Costello; Michael Y Sherman
Journal:  Prion       Date:  2007-04-16       Impact factor: 3.931

Review 6.  Protein folding and aggregation in bacteria.

Authors:  Raimon Sabate; Natalia S de Groot; Salvador Ventura
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

7.  Conformational transitions provoked by organic solvents in chicken egg ovalbumin: mimicking the local environment.

Authors:  Afshin Iram; Aabgeena Naeem
Journal:  Protein J       Date:  2013-01       Impact factor: 2.371

8.  Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment.

Authors:  Justin Legleiter; Gregor P Lotz; Jason Miller; Jan Ko; Cheping Ng; Geneva L Williams; Steve Finkbeiner; Paul H Patterson; Paul J Muchowski
Journal:  J Biol Chem       Date:  2009-06-02       Impact factor: 5.157

9.  Light chain amyloidosis - current findings and future prospects.

Authors:  Elizabeth M Baden; Laura A Sikkink; Marina Ramirez-Alvarado
Journal:  Curr Protein Pept Sci       Date:  2009-10       Impact factor: 3.272

10.  Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.

Authors:  Tanya L Poshusta; Laura A Sikkink; Nelson Leung; Raynell J Clark; Angela Dispenzieri; Marina Ramirez-Alvarado
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.